November 14, 2024
CS Pharmaceuticals Announces China Patent Grant
October 24, 2024
CS Pharmaceuticals announces appointment of Professor Bruce Robinson as Non Executive Director
February 20, 2024
CS Pharmaceuticals Announces Japan patent granted
September 20, 2023
CS Pharmaceuticals Announces US patent granted
July 28, 2023
CS Pharmaceuticals acquires AxeroVision Inc and pipeline for the treatment of Dry Eye Disease due to Meibomian Gland Dysfunction
January 31, 2023
CS Pharmaceuticals Announces Exclusive Licensing of the Chinese Commercialisation Rights to Bersiporocin from Daewoong
October 11, 2022
CS Pharmaceuticals Announces Exclusive Licensing of the Chinese Commercialisation Rights to IBE-814 from Ripple Therapeutics
June 1, 2022
CS Pharmaceuticals announces appointment of John Dawson CBE as Non Executive Director
February 15, 2022
CS Pharmaceuticals Announces Acquisition of Exclusive Chinese Commercialisation Rights to BRONCHITOL® from Pharmaxis
December 12, 2021
CS Pharmaceuticals announces strategic cooperation agreement with Medical Insight to jointly built a digital platform for rare diseases
November 29, 2021
CS Pharmaceuticals announces appointment of Roberto Lee as Non Executive Director
November 22, 2021
CS Pharmaceuticals announces strategic investment by Downing Ventures
September 13, 2021
CS Pharmaceuticals announces opening of Shanghai office to expand Regulatory and Clinical capabilities
June 22, 2021
CS Pharmaceuticals announces appointment of Professor Andrew Wilks as Non Executive Director
June 1, 2021
CS Pharmaceuticals announces appointment of Darren Mercer as Chief Executive Officer
June 1, 2021
CS Pharmaceuticals launches speciality pharmaceuticals business focused on China
